Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Meningococcal Disease

Meningococcal Disease

Part of Neisseriaceae Infections

8 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Meningococcal Disease

47 trials tracked for Meningococcal Disease: 27 in phase 3 or 4 and 2 with published results. The most-cited published study has 27 citations.

47Trials tracked
27Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 4 Phase 3 23 Phase 2 16 Other / NA 4
  1. Phase 3 Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects. Completed · 27 cited
  2. Phase 4 Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea Completed · 3 cited
  3. Phase 4 Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines Completed
  4. Phase 4 Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose Completed
  5. Phase 4 Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children Completed
  6. Phase 3 Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan. Completed
Show 41 more trials
  1. Phase 3 Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers Completed
  2. Phase 3 Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age Completed
  3. Phase 3 A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea Completed
  4. Phase 3 Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12 Completed
  5. Phase 3 Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age. Completed
  6. Phase 3 A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years Completed
  7. Phase 3 Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules Completed
  8. Phase 3 One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age Completed
  9. Phase 3 Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine Completed
  10. Phase 3 Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia Completed
  11. Phase 3 Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years. Completed
  12. Phase 3 Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10 Completed
  13. Phase 3 Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years Completed
  14. Phase 3 Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine Completed
  15. Phase 3 Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life Completed
  16. Phase 3 A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults Completed
  17. Phase 3 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Completed
  18. Phase 3 Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea Completed
  19. Phase 3 A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months Completed
  20. Phase 3 Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1 Completed
  21. Phase 3 Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years Completed
  22. Phase 2 Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers Completed
  23. Phase 2 Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine Completed
  24. Phase 2 A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158) Completed
  25. Phase 2 A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY Completed
  26. Phase 2 Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults Completed
  27. Phase 2 Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine Completed
  28. Phase 2 B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants Completed
  29. Phase 2 Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants Completed
  30. Phase 2 Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents Completed
  31. Phase 2 Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults Completed
  32. Phase 2 Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180) Completed
  33. Phase 2 Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older Completed
  34. Phase 2 Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines Completed
  35. Phase 2 Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents Completed
  36. Phase 2 Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months Completed
  37. Phase 2 Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers Completed
  38. N/A Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry Completed
  39. N/A 36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds Completed
  40. N/A Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine Completed
  41. N/A Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study Completed

Showing the 47 most-cited and recently-updated of 47 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Sequential reminders improved MenACWY coverage in unvaccinated youth and adults in Spain
Pediatrics RCT
Sequential reminders improved MenACWY coverage in unvaccinated youth and adults in Spain A Simple Two-Step Nudge Can Boost Crucial Teen Vaccination Rates
This randomized interventional study evaluated different reminder combinations for catch-up meningococcal ACWY vaccination among 66,891 unva…
A health system in Spain found that sending a physical letter followed by a text message was the most effective way to get more young people…
Apr 10, 2026
Novel Antibiotic-Resistant Neisseria meningitidis Strain Detected in the United States
Infectious Disease
Novel Antibiotic-Resistant Neisseria meningitidis Strain Detected in the United States Health officials detect new antibiotic-resistant meningitis strain in the United States
A public health report describes the detection of a novel, antibiotic-resistant strain of Neisseria meningitidis in the United States.
Health officials detected a new antibiotic-resistant strain of meningitis bacteria in the United States that requires close monitoring.
CDC Apr 6, 2026
CDC issues guidance on antibiotic prophylaxis for meningococcal contacts in ciprofloxacin-resistant areas
Infectious Disease
CDC issues guidance on antibiotic prophylaxis for meningococcal contacts in ciprofloxacin-resistant areas How should doctors protect people exposed to drug-resistant meningitis?
The CDC has issued guidance for health departments on selecting antibiotics for prophylaxis in close contacts of meningococcal disease patie…
CDC now directs health departments to switch antibiotics when meningitis cases become resistant to the standard drug ciprofloxacin.
CDC Apr 5, 2026
Outbreak report describes meningococcal disease cases in Virginia
Infectious Disease
Outbreak report describes meningococcal disease cases in Virginia What's happening with the meningococcal disease outbreak in Virginia?
An outbreak report describes cases of meningococcal disease in Virginia.
Virginia health officials report a meningococcal disease outbreak that can quickly become life-threatening if symptoms like fever and stiff …
CDC Apr 5, 2026
Observational report notes increase in meningococcal disease cases among US persons with HIV in 2022
Infectious Disease
Observational report notes increase in meningococcal disease cases among US persons with HIV in 2022 Report notes increase in meningococcal disease among people with HIV in the US
An observational report from the United States noted an increase in meningococcal disease cases among persons with HIV during 2022 compared …
A public health report found more cases of meningococcal disease among people with HIV in the US in 2022 compared to earlier years.
CDC Apr 5, 2026
ACIP Issues Updated Recommendations for Meningococcal Vaccination in the United States
Allergy & Immunology
ACIP Issues Updated Recommendations for Meningococcal Vaccination in the United States What's the latest advice on who should get the meningitis shot?
The Advisory Committee on Immunization Practices (ACIP) has published updated recommendations for the use of meningococcal vaccines in the U…
Updated CDC guidance now clarifies exactly who in the United States should get the meningitis vaccine to prevent serious infection.
CDC Apr 4, 2026
CDC updates MenB-4C vaccine dosing recommendations to align with new FDA label
Allergy & Immunology
CDC updates MenB-4C vaccine dosing recommendations to align with new FDA label What changed about the meningitis B vaccine schedule?
The CDC has issued updated recommendations for the Bexsero MenB-4C vaccine dosing interval and schedule.
CDC updated meningitis B vaccine timing to match new FDA label, ensuring doctors follow the latest official guidance for Bexsero shots.
CDC Apr 3, 2026
ACIP Issues Recommendations for Pfizer Pentavalent Meningococcal Vaccine in People 10+
Allergy & Immunology
ACIP Issues Recommendations for Pfizer Pentavalent Meningococcal Vaccine in People 10+ Who should get the new five-strain meningitis vaccine? Experts weigh in
The Advisory Committee on Immunization Practices has issued a recommendation report for the use of Pfizer's pentavalent meningococcal vaccin…
A national committee recommends Pfizer's new five-strain meningitis vaccine for people aged 10 and older in the United States.
CDC Apr 3, 2026

Questions about Meningococcal Disease

What should I know about the recent meningococcal disease outbreak in Virginia?

A 2022-2024 outbreak in Virginia involved a specific strain of bacteria that caused severe illness and deaths, particularly in adults aged 30-60, with no single common exposure identified.

Full answer →
Are there new meningococcal vaccination recommendations for people in the United States?

Yes, the CDC updated its meningococcal vaccination rules in 2020 to include new groups and schedules, and later adjusted dosing for the MenB-4C vaccine.

Full answer →